Published in Invest Ophthalmol Vis Sci on January 01, 2003
Recent perspectives in ocular drug delivery. Pharm Res (2008) 1.72
Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci (2006) 1.18
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06
Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol (2011) 0.96
Ocular delivery of macromolecules. J Control Release (2014) 0.91
Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine (2006) 0.88
Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol (2010) 0.85
Nanotechnology-mediated targeting of tumor angiogenesis. Vasc Cell (2011) 0.85
Applications of microscale technologies for regenerative dentistry. J Dent Res (2009) 0.85
Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev (2007) 0.84
Intravitreal devices for the treatment of vitreous inflammation. Mediators Inflamm (2012) 0.83
Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J (2012) 0.83
A biodegradable, sustained-released, prednisolone acetate microfilm drug delivery system effectively prolongs corneal allograft survival in the rat keratoplasty model. PLoS One (2013) 0.82
Aptamers as both drugs and drug-carriers. Biomed Res Int (2014) 0.79
Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology. Clin Ophthalmol (2007) 0.79
Drug delivery implants in the treatment of vitreous inflammation. Mediators Inflamm (2013) 0.78
One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study. Transl Vis Sci Technol (2014) 0.78
DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration. PLoS One (2014) 0.78
Current overview on challenges in regenerative endodontics. J Conserv Dent (2015) 0.77
Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics. Indian J Pharm Sci (2010) 0.76
The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide. J Ocul Pharmacol Ther (2013) 0.75
Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device. Pharmaceutics (2012) 0.75
Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. J Pers Med (2013) 0.75
Delivery systems for in vivo use of nucleic Acid drugs. Drug Target Insights (2007) 0.75
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01
Age-related macular degeneration. N Engl J Med (2008) 7.49
A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J (2004) 5.33
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology (2005) 3.20
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J (2002) 2.90
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology (2011) 2.65
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 2.57
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol (2006) 2.52
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 2.52
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2005) 2.43
Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med (2003) 2.39
Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci (2006) 2.37
Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol (2013) 2.32
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis. Proc Natl Acad Sci U S A (2007) 2.20
Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. Proc Natl Acad Sci U S A (2010) 2.20
VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci (2003) 2.09
Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol (2007) 2.08
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol (2005) 1.97
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology (2003) 1.96
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest (2002) 1.95
DNA sequence variants in the LOXL1 gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity. BMC Med Genet (2008) 1.95
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol (2002) 1.71
Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol (2010) 1.71
The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology (2002) 1.70
Histologic correlation of in vivo optical coherence tomography images of the human retina. Am J Ophthalmol (2006) 1.68
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J (2002) 1.63
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol (2002) 1.57
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol (2002) 1.53
Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology (2009) 1.51
Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology (2005) 1.47
Proton irradiation for peripapillary and parapapillary melanomas. Arch Ophthalmol (2011) 1.45
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci (2004) 1.45
Characterization of cytokine responses to retinal detachment in rats. Mol Vis (2006) 1.43
Caspase activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci (2003) 1.40
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol (2004) 1.39
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci (2007) 1.38
Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. Arch Ophthalmol (2007) 1.37
Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration. Proc Natl Acad Sci U S A (2012) 1.37
Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One (2012) 1.35
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.34
Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci (2007) 1.33
Predictors of visual outcome and choroidal neovascular membrane formation after traumatic choroidal rupture. Arch Ophthalmol (2006) 1.32
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci (2007) 1.32
Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration. Ophthalmology (2007) 1.30
The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci (2003) 1.28
FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci (2004) 1.24
The NEI/NCBI dbGAP database: genotypes and haplotypes that may specifically predispose to risk of neovascular age-related macular degeneration. BMC Med Genet (2008) 1.22
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci (2006) 1.22
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci (2003) 1.22
Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes (2003) 1.21
Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2005) 1.20
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol (2004) 1.19
Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol (2005) 1.17
VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci (2003) 1.17
In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci (2011) 1.14
Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J (2008) 1.14
Preliminary results of gene therapy for retinal degeneration. N Engl J Med (2008) 1.14
Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol (2009) 1.13
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology (2007) 1.12
Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci (2002) 1.11
Treatment of metastatic tumors of the choroid with proton beam irradiation. Ophthalmology (2005) 1.11
HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest (2008) 1.11
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis (2006) 1.10
Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular degeneration. Hum Genomics (2011) 1.08
Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J (2007) 1.08
Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration. Am J Ophthalmol (2009) 1.08
Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol (2005) 1.07
Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci (2003) 1.07
In vivo imaging of endothelial injury in choriocapillaris during endotoxin-induced uveitis. FASEB J (2008) 1.06
Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea (2003) 1.05
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol (2009) 1.04
Reduced photoreceptor damage after photodynamic therapy through blockade of nitric oxide synthase in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci (2007) 1.04
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol (2007) 1.03
Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci (2002) 1.03
Endogenous endostatin inhibits choroidal neovascularization. FASEB J (2007) 1.03
Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am (2006) 1.02
Tumor necrosis factor-alpha mediates photoreceptor death in a rodent model of retinal detachment. Invest Ophthalmol Vis Sci (2011) 1.02